Insider Selling: MaxCyte, Inc. (NASDAQ:MXCT) EVP Sells $70,261.04 in Stock

MaxCyte, Inc. (NASDAQ:MXCT) EVP Thomas M. Ross sold 15,476 shares of the business’s stock in a transaction that occurred on Thursday, August 1st. The shares were sold at an average price of $4.54, for a total value of $70,261.04. Following the completion of the sale, the executive vice president now owns 25,000 shares of the company’s stock, valued at approximately $113,500. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

MaxCyte Stock Down 8.3 %

Shares of MaxCyte stock opened at $4.08 on Thursday. The company has a market cap of $427.68 million, a PE ratio of -11.66 and a beta of 1.42. The business has a 50 day moving average of $4.43 and a 200 day moving average of $4.42. MaxCyte, Inc. has a 52 week low of $2.45 and a 52 week high of $5.55.

MaxCyte (NASDAQ:MXCT) last posted its quarterly earnings data on Tuesday, August 6th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.05. The business had revenue of $10.43 million during the quarter, compared to the consensus estimate of $8.20 million. MaxCyte had a negative return on equity of 15.68% and a negative net margin of 83.00%. During the same quarter in the prior year, the company earned ($0.10) earnings per share. On average, research analysts anticipate that MaxCyte, Inc. will post -0.5 earnings per share for the current year.

Hedge Funds Weigh In On MaxCyte

A number of institutional investors have recently added to or reduced their stakes in the company. Cadian Capital Management LP bought a new position in MaxCyte in the fourth quarter worth $26,531,000. Vanguard Group Inc. raised its holdings in MaxCyte by 1.2% in the first quarter. Vanguard Group Inc. now owns 5,347,112 shares of the company’s stock worth $22,404,000 after purchasing an additional 65,004 shares in the last quarter. Massachusetts Financial Services Co. MA raised its holdings in MaxCyte by 29.9% in the fourth quarter. Massachusetts Financial Services Co. MA now owns 2,537,114 shares of the company’s stock worth $11,924,000 after purchasing an additional 584,372 shares in the last quarter. River Global Investors LLP grew its stake in shares of MaxCyte by 24.4% in the first quarter. River Global Investors LLP now owns 1,888,642 shares of the company’s stock worth $7,973,000 after acquiring an additional 369,996 shares during the last quarter. Finally, Mudita Advisors LLP grew its stake in shares of MaxCyte by 35.3% in the fourth quarter. Mudita Advisors LLP now owns 1,881,349 shares of the company’s stock worth $8,842,000 after acquiring an additional 490,491 shares during the last quarter. Institutional investors own 68.81% of the company’s stock.

Analyst Ratings Changes

Separately, Stephens reiterated an “overweight” rating and issued a $11.00 price objective on shares of MaxCyte in a research report on Tuesday, April 23rd.

MaxCyte Company Profile

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.